A Canadian nonprofit organization has launched a collaborative study to examine the effectiveness of psilocybin-assisted psychotherapy on patients who have received federal exemptions to treat their end-of-life distress.
TheraPsil, a British Columbia-based patient advocacy group, has partnered with researchers from McGill University and the Centre for Psychedelic Research at Imperial College London for this first-ever quantitative research project aimed at understanding the impact of psilocybin-assisted psychotherapy on Canadian palliative patients who have received Section 56 exemptions under the Canadian Controlled Drugs and Substances Act (CDSA).
Share this post
